Joint source of Boehringer Ingelheim GmbH and Pfizer Inc

INGELHEIM, Germany - - New UPLIFT(R) Analysis Shows Tiotropium Significantly Improves Lung Function and Quality of Life in COPD Patients With Early Stage Disease - Not for US Media A new analysis of the landmark UPLIFT(R) trial, published today in the Lancet, shows that tiotropium (SPIRIVA(R) Handihaler(R) 18 micro g) administered to Chronic Obstructive Pulmonary Disease (COPD) patients with moderate disease severity (GOLD - Global Initiative for Chronic Obstructive Lung Disease - Stage II) produced significant and sustained improvements in lung function for up to 4 years.[1] This pre-specified subgroup analysis involved 2,739 patients - the largest group of early stage COPD patients treated with a long-acting anticholinergic in a randomised, placebo-controlled study.